Revance Therapeutics Inc (RVNC)

[DewDiligence]

Re: EOLS

A 1-point improvement relative to baseline—the metric EOLS is using to present its double-dose dataset—is a much "softer" metric than none-or-mild status, the metric favored by RVNC and regulatory authorities. Specifically, patients who had severe wrinkles at baseline need only improve to having moderate wrinkles using EOLS' 1-point metric to be counted as successes in EOLS' duration tally.

Few patients and injectors would consider having moderate wrinkles at a given time point to mean that the toxin is still working at that point.